COMMUNIQUÉS West-GlobeNewswire

Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors
11/03/2024
- First patient dosed with IMM-1-104 in combination with modified gemcitabine plus nab-paclitaxel for first-line treatment of pancreatic ductal adenocarcinoma (PDAC) - - Phase 2a portion of Phase 1/2a clinical trial [...]
ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients
11/03/2024
Dose ordered and robust HiSCRs were rapidly demonstrated with about a third of patients achieving HiSCR100, or resolution of abscesses and nodules, by week 16 and through week 32 Deep and consistent HiSCR responses were [...]
Daxor Announces Sales to Three New Hospitals Furthering Expansion of Its User Base
11/03/2024
Oak Ridge, TN, March 11, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology today announces the expansion of blood volume analysis (BVA) in three new [...]
Garry Lowenthal Joins PetVivo Holdings, Inc. as the Chief Financial Officer
11/03/2024
MINNEAPOLIS, MN, US, March 11, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical [...]
Biora Therapeutics Further Reduces Net Debt and Monetizes Legacy Asset
11/03/2024
Monetization of legacy asset brings in $3 million in nondilutive capital Convertible notes exchange brings in another $2.8 million in new capital and reduces Biora’s net debt SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE [...]
Tonix Pharmaceuticals Reports Improvement in “Brain Fog,” in Fibromyalgia Patients Treated with Tonmya™ in RESILIENT, an NDA-Enabling Phase 3 Clinical Trial, at the 6th International Congress on Controversies in Fibromyalgia
11/03/2024
Phase 3 RESILIENT study of Tonmya met its primary endpoint of daily pain reduction (p=0.00005) and achieved statistically significant improvement on all six key pre-specified secondary endpoints with effect sizes on [...]
Arcutis Promotes Todd Tucker to Chief Human Resources Officer
11/03/2024
Industry veteran with over 25 years’ experience will continue to advance the company culture and grow the capabilities of Arcutis’ workforce WESTLAKE VILLAGE, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- Arcutis [...]
R1 RCM Forms Special Committee to Evaluate Strategic Alternatives
11/03/2024
MURRAY, Utah, March 11, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM) (“R1” or the “Company”), a leading provider of technology-driven solutions that transform the patient experience and financial performance of [...]
Journal of Neurosurgery Publication Demonstrates Distinct Advantages of ClearPoint Prism® Neuro Laser Therapy System
11/03/2024
ClearPoint Prism Now Being Used with Recently FDA Cleared and Launched SmartFrame Array® 1.2 Software SOLANA BEACH, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a [...]
Nusano Opens Radiochemistry Laboratory to Advance Isotope Commercialization and Customer Collaboration
11/03/2024
Lu-177 shipments expected to begin early 2025, followed by Ac-225 WEST VALLEY CITY, Utah, March 11, 2024 (GLOBE NEWSWIRE) -- Nusano, a physics company transforming the production of medical radioisotopes, cut the ribbon [...]
BioVie Announces Pipeline Update and Near-Term Clinical Priorities
11/03/2024
Recently completed financing provides sufficient funds for near-term Parkinson’s Disease priority Plans for Phase 2b trial of NE3107 as first-line monotherapy for Parkinson’s Disease being finalized with targeted launch [...]
DiagnaMed Accelerates Commercialization Initiatives of CERVAI™ Brain Health AI Solution
11/03/2024
TORONTO, March 11, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), an artificial intelligence digital healthcare company, is pleased to announce that it has [...]
IntelGenx Enters Into a Third Amended and Restated Loan Agreement With atai Life Sciences
11/03/2024
SAINT LAURENT, Quebec, March 11, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the “ Company ”) announces that its wholly-owned subsidiary, IntelGenx Corp. (“ IntelGenx Corp. ”), has [...]
BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024
11/03/2024
MAINZ, Germany, March 11, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected candidates from its oncology pipeline at the American Association for Cancer [...]
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
11/03/2024
Lexeo announces $95.0M equity financing, which in addition to 2023 year-end cash and cash equivalents of $121.5M, extends runway to fund operations into 2027 Reports frataxin protein expression data from a subset of the [...]
Applied UV’s Subsidiary Files Patent Application for New Industry Disruptive Integrated Disinfection System for Healthcare Facilities
11/03/2024
Aligns with Company’s strategic focus on bringing to market state-of-the-art advanced disinfection systems NEW YORK, NY, March 11, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Applied UV, Inc. (“Applied UV” or the “ [...]
Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing
11/03/2024
Lexeo extends runway into 2027 with private placement co-led by Braidwell LP and Adage Capital Partners LP, with participation from new and existing investors including RA Capital Management, Surveyor Capital (a Citadel [...]
Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update
11/03/2024
Commercial launch of INPEFA ® (sotagliflozin) continues to progress. with increasing demand across the cardiology community and improving payer access Patient enrollment underway in PROGRESS, a Phase 2b study of LX9211 [...]
Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities
11/03/2024
THE WOODLANDS, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced it has entered into a securities purchase agreement (the “purchase agreement”) for a [...]

Pages